(IN BRIEF) Novartis has agreed to acquire SNV4818 from Synnovation Therapeutics, a next-generation PI3Kα inhibitor designed to selectively target mutations in HR+/HER2- breast cancer. The therapy, currently in Phase 1/2 clinical trials, aims to improve treatment tolerability by focusing on … Read the full press release →
Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged Breast Cancer Treatment, cancer research, clinical trials Phase 1/2, HR positive HER2 negative, Novartis, Novartis Strengthens Breast Cancer Portfolio with Acquisition of Next Generation Selective PI3Kα Therapy, oncology pipeline, pharmaceutical acquisition, PI3Kα inhibitor, PIK3CA mutation, Pikavation Therapeutics, precision medicine, SNV4818, solid tumors, Synnovation Therapeutics, targeted therapy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
